Compound Heterozygous Hemochromatosis: Long-Term Outcomes
People with C282Y/H63D mutations in the HFE gene were no more likely than people with neither mutation to develop hemochromatosis-related morbidity.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)